Research programme: respiratory disorder therapeutics - Pearl Therapeutics

Drug Profile

Research programme: respiratory disorder therapeutics - Pearl Therapeutics

Alternative Names: Formoterol/glycopyrrolate/mometasone - Nektar Therapeutics; PT002/PT009

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pearl Therapeutics
  • Class Androstadienes; Corticosteroids; Ethanolamines; Phenethylamines; Pregnenediones; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Respiratory tract disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA (Inhalation, Aerosol)
  • 30 Nov 2013 Preclinical development is ongoing in USA
  • 27 Jun 2013 Pearl Therapeutics has been acquired by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top